ALNY Alnylam Pharmaceuticals, Inc. | US02043Q1076
| Metric | Current | 31.03.2026 | 31.12.2025 | 30.09.2025 |
|---|---|---|---|---|
| Market Cap | 36.284.710.912 | 44.152.615.628,42 | 52.639.315.592,04 | 60.096.696.000 |
| Enterprise Value | 36.245.716.992 | 43.714.894.628,42 | 52.260.454.592,04 | 59.914.899.000 |
| Trailing P/E | 68,46 | 76,49 | 149,13 | 360,82 |
| Forward P/E | 20,22 | - | - | - |
| Price to Sales | 8,46 | 10,3 | 14,17 | 22,96 |
| Price to Book | 33,72 | 41,06 | 66,7 | 256,94 |
| EV/Revenue | 8,46 | 10,2 | 14,07 | 22,9 |
| EV/EBITDA | 44,92 | 48,07 | 77,39 | 118,23 |